The estimated Net Worth of Trading S.A. Ares is at least $64 Million dollars as of 12 October 2021. Trading Ares owns over 143,796 units of Precigen Inc stock worth over $20,027,737 and over the last 4 years Trading sold PGEN stock worth over $43,965,460.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Trading Ares PGEN stock SEC Form 4 insiders trading
Trading has made over 37 trades of the Precigen Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Trading sold 143,796 units of PGEN stock worth $667,213 on 12 October 2021.
The largest trade Trading's ever made was buying 6,758,400 units of Precigen Inc stock on 7 October 2020 worth over $25,006,080. On average, Trading trades about 365,129 units every 10 days since 2020. As of 12 October 2021 Trading still owns at least 20,647,152 units of Precigen Inc stock.
You can see the complete history of Trading Ares stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Trading Ares's mailing address?
Trading's mailing address filed with the SEC is RUE DE L'OURIETTE 151, ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE, V8, 1170.
Insiders trading at Precigen Inc
Over the last 5 years, insiders at Precigen Inc have traded over $44,216,787 worth of Precigen Inc stock and bought 52,689,457 units worth $114,197,137 . The most active insiders traders include Randal J Kirk, Trading S.A. Ares und Helen Sabzevari. On average, Precigen Inc executives and independent directors trade stock every 9 days with the average trade being worth of $358,866. The most recent stock trade was executed by Randal J Kirk on 9 August 2024, trading 23,529,411 units of PGEN stock currently worth $19,999,999.
What does Precigen Inc do?
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
What does Precigen Inc's logo look like?
Complete history of Trading Ares stock trades at Precigen Inc
Precigen Inc executives and stock owners
Precigen Inc executives and other stock owners filed with the SEC include:
-
Randal Kirk,
Executive Chairman of the Board -
Dr. Helen Sabzevari MPH, Ph.D.,
Pres, CEO & Director -
Donald Lehr,
Chief Legal Officer -
Rick Sterling,
Chief Financial Officer -
Jeffrey Perez,
Senior Vice President - Intellectual Property Affairs -
Helen Sabzevari,
President, Chief Executive Officer, President - Precigen, Inc. -
Donald P. Lehr,
Chief Legal Officer & Corp. Sec. -
Jeffrey Thomas Perez,
Sr. VP of Intellectual Property Affairs -
Jeffrey Kindler,
Independent Director -
Robert Shapiro,
Lead Independent Director -
Cesar Alvarez,
Independent Director -
James Turley,
Independent Director -
Dean Mitchell,
Independent Director -
Fred Hassan,
Independent Director -
Vinita Gupta,
Independent Director -
Steven Frank,
Independent Director -
Marie Rossi,
VP of Communications -
Steven Harasym,
Head of Investor Relations -
James Vincent Lambert,
Interim Principal Accounting Officer -
Rutul R. Shah,
Head of Operations & Portfolio -
Harry Thomasian Jr.,
Chief Financial Officer -
Dr. Thomas D. Reed,
Founder & Chief Science Officer -
Randal J. Kirk,
Exec. Chairman -
Harry Jr. Thomasian,
Chief Financial Officer -
Nancy H Agee,
Director -
Rutul R Shah,
Chief Operating Officer -
D. Bradford Osborne,
VP, Finance and Accounting -
Trading S.A. Ares,
10% owner -
Phil Tennant,
Chief Commercial Officer